pISSN 2234-3806eISSN 2234-3814
Table. 1.
Clinical characteristics of patients with a hematologic diagnosis with t(3;21)
| Characteristics | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| Diagnosis |
MDS-EB1 | t-MDS | t-MDS | MDS-U |
| Age |
23/male | 17/male | 66/male | 72/female |
| Underlying disease (age, yr) | MDS (2) | Osteosarcoma (16) | Rectal cancer (59) | Bladder cancer (67) |
| Chemotherapy or RT | None | Methotrexate, ifosfamide, etoposide, carboplatin, busulfan, melphalan | Oxaliplatin, folinic acid, fluorouracil | None |
| Survival |
78 months (alive) | 31 months | 37 months (alive) | 36 months |
| CBC (Hb, WBC, PLT) | 60 g/L, 1,800 × 106/L, 60 × 109/L | 119 g/L, 2,980 × 106/L, 73 × 109/L | 117 g/L, 2,130 × 106/L, 47 × 109/L | 74 g/L, 900 × 106/L, 48 × 109/L |
| Blast count in BM |
9.0% | < 5% | < 5% | < 5% |
| Dysplasia | Dysgranulopoiesis | Dyserythropoiesis, dysmegakaryopoiesis | Dysmegakaryopoiesis | N/A |
| Chromosome (G-banding) |
46,XY,t(3;21)(q26.2;q22) | 45,XY,t(3;21)(q26.2;q22),–7 | 46,XY,t(3;21)(q26.2;q22) | 46,XX,t(3;21)(q26.2;q22) |
| Positive (52.7%) | Positive (46%) | Positive (50%) | N/A | |
| Somatic variant genes (VAF, %) | ||||
*Initial hematologic diagnosis in the presence of a
Abbreviations: MDS, myelodysplastic syndrome; MDS-EB1, myelodysplastic syndrome with excess blasts 1; t-MDS, treatment-related myelodysplastic syndrome; MDS-U, myelodysplastic syndrome, unclassifiable; RT, radiotherapy; CBC, complete blood count; BM, bone marrow; N/A, not available due to poor quality; VAF, variant allele frequency; WBC, white blood cell; PLT, platelet.
© Ann Lab Med